Navigation Links
CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
Date:8/12/2009

es for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. BIOGLUE Aesthetic(TM) Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty (brow lift) in reconstructive plastic surgery and is distributed by a third party for this indication. The Company's BioFoam((R)) Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. CryoLife distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the European Community and Canada for cardiac, vascular, and general surgery, subject to certain exclusions.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated effectiveness, benefits and indications for use of CryoPatch SG and the anticipated U.S. market it would address, as well as the timing of use of the SynerGraft technology. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that CryoPatch SG may not perform as well as expected or provide all of the benefits anticipated, nor may the first shipments of CryoPatch SG occur as expected, that the CryoPatch SG has a one year shelf life, and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CryoLife Reports Record First Quarter Revenues of $26.7 Million
2. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
3. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
4. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
5. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
6. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
7. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
8. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
9. CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2008 Financial Results
10. CryoLife Hosts Worldwide Surgical Congress for the Ross Procedure
11. CryoLife Expands Distribution of Hemostase MPH(R) to Canada through Sorin Group Canada, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" ... high-quality,pharmaceutical grade glucose products in China, today announced ... months ended September 30, 2008,after the close of ... will conduct a conference call on Friday, November ...
... class drug illustrates early signal of transport of ... Exchange Symbol: RVX CALGARY, Nov. 10 /PRNewswire-FirstCall/ ... with its lead drug,RVX-208, a first in class ... Phase 1a clinical trial found that treatment with ...
... Overall Survival, Summary: Three ofatumumab Abstracts Have Been Accepted for ... ... Genmab A/S (OMX: GEN),announced today that three ofatumumab (HuMax-CD20(R)) ... of Hematology Annual,Meeting and Exposition (ASH) December 6-9, 2008. Updated ...
Cached Biology Technology:Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 2Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 2RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 3RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 4Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 2Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 3
(Date:12/19/2014)... 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... in July 2012, Apple introduced the fingerprint reading ... the only device of Apple incorporating such a ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and ... addition of the "Micro Market Monitor: North America ... http://photos.prnewswire.com/prnh/20130307/600769 ... grow at a CAGR of 3.6% from 2014 to ... in this market, Canada is ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... By studying mice with skin cancer, researchers at the Huntsman ... to inhibit a mutant gene found in up to 30 ... this gene are important in cell signaling, or communication among ... gene that has been shown to promote the growth of ...
... when and where certain proteins are made is crucial ... proteins, information from DNA is transcribed into RNA molecules ... of proteins. But not all genes code for proteins--some ... interfere with--and therefore control--the production of proteins. A new ...
... partially differentiated stem cells with gene therapy can promote the ... spinal cords of rats, a new study shows. The treatment, ... improves the animals' motor function and electrical conduction from the ... to new ways of treating spinal cord injury in humans. ...
Cached Biology News:Scientists inhibit cancer gene 2MicroRNAs play a big part in gene regulation - and evolution 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Biology Products: